Supplemental material
Drug Delivery
Volume 24, 2017 - Issue 1
Related Research Data
Cancer statistics, 2012
Source:
Wiley
Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells.
Source:
Microbiology Society
Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide
Source:
Elsevier BV
Development of multidrug-resistance convertors: sense or nonsense?
Source:
Springer Science and Business Media LLC
Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Source:
Elsevier BV
Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Source:
American Chemical Society (ACS)
Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo
Source:
Elsevier BV
Nanotechnology approaches for personalized treatment of multidrug resistant cancers.
Source:
Elsevier BV
Dendrimer Versus Linear Conjugate: Influence of Polymeric Architecture on the Delivery and Anticancer Effect of Paclitaxel
Source:
American Chemical Society (ACS)
From bench to clinic with apoptosis-based therapeutic agents
Source:
Springer Science and Business Media LLC
Antitumour activity of ANG1005
Source:
Wiley
PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Source:
Elsevier BV
Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells.
Source:
American Chemical Society (ACS)
Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles.
Source:
Elsevier BV
Cell-Penetrating Conjugates for Cancer Therapy
Source:
Wiley
Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer
Source:
Springer Science and Business Media LLC
Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations
Source:
(:unav)
Recent advances in the use of cell-penetrating peptides for medical and biological applications.
Source:
Elsevier BV
Paclitaxel and Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
Source:
Wiley
Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy
Source:
American Chemical Society (ACS)
Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin.
Source:
Elsevier BV
Tumor Targeting and pH-Responsive Polyelectrolyte Complex Nanoparticles Based on Hyaluronic Acid-Paclitaxel Conjugates and Chitosan for Oral Delivery of Paclitaxel
Source:
Springer Science and Business Media LLC
Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy.
Source:
Wiley
Nanopreparations to overcome multidrug resistance in cancer
Source:
Elsevier BV
Tubulin inhibitors in non-small cell lung cancer: looking back and forward.
Source:
Informa Healthcare
Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse
Source:
Elsevier BV
Mitosis and apoptosis: how is the balance set?
Source:
Elsevier BV
Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs
Source:
MDPI AG
Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.
Source:
American Chemical Society (ACS)
Controlled release of free doxorubicin from peptide-drug conjugates by drug loading.
Source:
Elsevier BV
755OA RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE DOCETAXEL/PREDNISONE (DP) TO DP PLUS CUSTIRSEN IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Source:
Elsevier BV
Taxane resistance in breast cancer: A closed HER2 circuit?
Source:
Elsevier BV
Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells.
Source:
American Chemical Society (ACS)
Linking provided by
